Annual Report 2019 is available for download on the Pharming website today

Pharming Group N.V. announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension of the indication for RUCONEST® to the European Commission.

Pharming Group N.V. announces that it has been included in the Euronext Amsterdam Midkap index (AMX).

Pharming Group N.V. today announced that its Chief Financial Officer, Robin Wright, has decided (for family reasons) not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and that, as result of this decision, his term with the Company will end as at that date.

Pharming Group N.V. today announced it has also received US Food and Drug Administration (FDA) approval of Pharming’s Prior Approval Supplement to add the new Netherlands production facility of starting material to the Biologics License Application (BLA) to support its lead product, RUCONEST®.

The Company will hold a conference call at 13.00 CET/07.00 EST today. Dial in details can be found on page 12 of the press release.

Pharming Group N.V. today announced it has received European Medicines Agency (EMA) approval of a Type II Variation for a new production facility for its lead product, RUCONEST®.

Pharming Group N.V. announces today the placement of €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The offer was fully subscribed. The Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, South Africa, and Japan.

Pharming Group N.V. today announces the launch of an offering (the “Offering”) of approximately €125 million of senior unsecured convertible bonds due 2025 (the “Bonds”). The net proceeds of the issue of the Bonds will be used to redeem the approximately US$ 56 million loan with Orbimed Advisors in full, thereby reducing the Company’s financing costs and extending its debt maturity through the period to approval of most of the Company’s existing pipeline. The balance of the net proceeds will be used to support capital expenditure in relation to the expansion of the commercialization and manufacturing infrastructure of the Company, and serve as funding for the launch of Pharming’s recently acquired leniolisib product and for additional acquisitions/in-licensing opportunities.